Media stories about Catalyst Biosciences (NASDAQ:CBIO) have trended somewhat negative recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalyst Biosciences earned a news sentiment score of -0.02 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 47.1784152155204 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

A number of brokerages recently issued reports on CBIO. Ladenburg Thalmann Financial Services began coverage on shares of Catalyst Biosciences in a report on Tuesday, June 6th. They issued a “buy” rating and a $11.00 price objective for the company. Chardan Capital began coverage on shares of Catalyst Biosciences in a report on Monday, June 12th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Zacks Investment Research cut shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a report on Monday, June 5th.

Shares of Catalyst Biosciences (CBIO) traded down 0.90% during midday trading on Friday, reaching $3.32. 36,364 shares of the company were exchanged. Catalyst Biosciences has a 52-week low of $3.11 and a 52-week high of $21.30. The company’s market capitalization is $14.31 million. The stock has a 50-day moving average price of $3.76 and a 200 day moving average price of $4.97.

Catalyst Biosciences (NASDAQ:CBIO) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.46) by $1.07. Catalyst Biosciences had a negative net margin of 3,127.92% and a negative return on equity of 92.61%. The business had revenue of $0.11 million during the quarter. Equities research analysts expect that Catalyst Biosciences will post ($7.08) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Critical News Coverage Somewhat Unlikely to Impact Catalyst Biosciences (CBIO) Share Price” was reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Insider Buying and Selling by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Ratings for Catalyst Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.